Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosis
Cory Wilson, Tinne C.J. Mertens, Pooja Shivshankar, Weizen Bi, Scott D. Collum, Nancy Wareing, Junsuk Ko, Tingting Weng, Ram P. Naikawadi, Paul J. Wolters, Pascal Maire, Soma S.K. Jyothula, Rajarajan A. Thandavarayan, Dewei Ren, Nathan D. Elrod, Eric J. Wagner, Howard J. Huang, Burton F. Dickey, Heide L. Ford, Harry Karmouty-Quintana
Cory Wilson, Tinne C.J. Mertens, Pooja Shivshankar, Weizen Bi, Scott D. Collum, Nancy Wareing, Junsuk Ko, Tingting Weng, Ram P. Naikawadi, Paul J. Wolters, Pascal Maire, Soma S.K. Jyothula, Rajarajan A. Thandavarayan, Dewei Ren, Nathan D. Elrod, Eric J. Wagner, Howard J. Huang, Burton F. Dickey, Heide L. Ford, Harry Karmouty-Quintana
View: Text | PDF
Research Article Pulmonology

Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosis

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options. The role of the developmental transcription factor Sine oculis homeobox homolog 1 (SIX1) in the pathophysiology of lung fibrosis is not known. IPF lung tissue samples and IPF-derived alveolar type II cells (AT2) showed a significant increase in SIX1 mRNA and protein levels, and the SIX1 transcriptional coactivators EYA1 and EYA2 were elevated. Six1 was also upregulated in bleomycin-treated (BLM-treated) mice and in a model of spontaneous lung fibrosis driven by deletion of Telomeric Repeat Binding Factor 1 (Trf1) in AT2 cells. Conditional deletion of Six1 in AT2 cells prevented or halted BLM-induced lung fibrosis, as measured by a significant reduction in histological burden of fibrosis, reduced fibrotic mediator expression, and improved lung function. These effects were associated with increased macrophage migration inhibitory factor (MIF) in lung epithelial cells in vivo following SIX1 overexpression in BLM-induced fibrosis. A MIF promoter–driven luciferase assay demonstrated direct binding of Six1 to the 5′-TCAGG-3′ consensus sequence of the MIF promoter, identifying a likely mechanism of SIX1-driven MIF expression in the pathogenesis of lung fibrosis and providing a potentially novel pathway for targeting in IPF therapy.

Authors

Cory Wilson, Tinne C.J. Mertens, Pooja Shivshankar, Weizen Bi, Scott D. Collum, Nancy Wareing, Junsuk Ko, Tingting Weng, Ram P. Naikawadi, Paul J. Wolters, Pascal Maire, Soma S.K. Jyothula, Rajarajan A. Thandavarayan, Dewei Ren, Nathan D. Elrod, Eric J. Wagner, Howard J. Huang, Burton F. Dickey, Heide L. Ford, Harry Karmouty-Quintana

×

Figure 10

Elevated MIF levels in IPF and in experimental models of lung fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Elevated MIF levels in IPF and in experimental models of lung fibrosis.
...
(A) MIF transcript levels in control or IPF lung samples (n = 8 per group). (B–D) Lung Mif transcript levels from BLM treated SPC-rtTA or AT2-SIX1OE mice (n = 5 per group) (B); BLM-treated iAT2Cre or iAT2Six1–/– treated prophylactically (n = 6 [iAT2Cre], n = 7 [iAT2 Six1–/– ]) (C) or therapeutically, starting on day 15 of BLM (n = 5 per group) (D) with tamoxifen to delete AT2-Six1. (E) MIF BALF levels from BLM treated SPC-rtTA or AT2-SIX1OE mice; BLM-treated iAT2Cre or iAT2Six1–/– treated prophylactically or therapeutically with tamoxifen. (F) Absorbance values of WST-1 assay at 24 hours read at 450 nm for control human lung fibroblasts (n = 12) with or without 100 ng/mL recombinant human MIF. (G) Human lung fibroblasts treated with a dose response (4–400 ng/mL) of MIF in vitro for 48 hours stained with α-SMA (red signal) and counter-stained with DAPI. Scale bar: 50 μm. (H) Quantification of SMA fluorescent signal using integration of per cell fluorescence pixel intensity using an automated fluorescence cell cytometer (n = 5 per group). *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001 refer to Kruskal-Wallis test with the 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli post hoc test (A), Student’s t test with Welch Correction (B–D, and F), and Browne-Forsythe and Welch ANOVA tests with Dunnett’s T3 multiple comparison test (E and H).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts